Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 3.7%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report)'s stock price rose 3.7% on Monday . The stock traded as high as 1.55 and last traded at 1.53. Approximately 4,342,382 shares traded hands during trading, an increase of 18% from the average daily volume of 3,688,101 shares. The stock had previously closed at 1.47.

Analyst Upgrades and Downgrades

CATX has been the subject of several analyst reports. B. Riley raised their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the company a "buy" rating in a report on Tuesday, April 9th. Oppenheimer reiterated an "outperform" rating and issued a $1.50 price objective (up from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st.

Perspective Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07. The stock has a market cap of $897.99 million, a price-to-earnings ratio of -15.30 and a beta of 1.56.

Insider Buying and Selling

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average cost of 0.95 per share, with a total value of 57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares in the company, valued at 110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average cost of 0.95 per share, with a total value of 57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares in the company, valued at 110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Markus Puhlmann acquired 280,000 shares of Perspective Therapeutics stock in a transaction on Wednesday, January 24th. The stock was purchased at an average cost of 0.50 per share, for a total transaction of 140,000.00. Following the purchase, the insider now owns 1,375,425 shares in the company, valued at 687,712.50. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 60,758,439 shares of company stock valued at $57,576,503. Corporate insiders own 5.72% of the company's stock.

Institutional Trading of Perspective Therapeutics

Large investors have recently added to or reduced their stakes in the company. Wealth Effects LLC bought a new position in shares of Perspective Therapeutics during the 3rd quarter valued at approximately $30,000. Charles Schwab Investment Management Inc. bought a new position in shares of Perspective Therapeutics during the 3rd quarter valued at approximately $32,000. Creative Planning bought a new position in shares of Perspective Therapeutics during the 3rd quarter valued at approximately $35,000. Bank of New York Mellon Corp bought a new position in shares of Perspective Therapeutics during the 3rd quarter valued at approximately $42,000. Finally, Taylor & Morgan Wealth Management LLC increased its position in shares of Perspective Therapeutics by 8.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company's stock valued at $251,000 after purchasing an additional 50,000 shares during the last quarter. Institutional investors own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.